萎缩性胃炎与胃癌前病变诊疗研究的关键问题及其对策

唐旭东; 张泰; 卞立群; 王萍

doi:10.3969/j.issn.1671-038X.2023.05.01

萎缩性胃炎与胃癌前病变诊疗研究的关键问题及其对策

- 1.
  中国中医科学院西苑医院脾胃病研究所(北京，100091)
- 2.
  中国中医科学院研究生院
基金项目:
中国中医科学院科技创新工程(No：CI2021A01004)；中医药治疗难治性胃肠病的传承与创新团队(No：ZYYCXTD-C-202010)；脾胃病学科传承创新团队(No：CI2021B005)

详细信息

作者简介:
唐旭东，医学博士，主任医师，教授，博士研究生导师，博士后合作导师，国际欧亚科学院院士，第六批全国老中医药专家学术经验继承工作指导老师，中国中医科学院首席研究员，全国政协委员。现任中国中医科学院副院长兼西苑医院脾胃病研究所所长、国家中医药管理局脾虚重点研究室主任、中药临床疗效与安全性评价国家工程实验室主任。兼任中华中医药学会脾胃病分会主任委员，国家级脾胃病重点专科、局级重点专科、学科带头人，《中国中西医结合消化杂志》主编等。先后主持国家级、省部级课题30余项，制定国家级及行业、团体标准68项，主编学术专著12部，发表学术论文320余篇(其中SCI 30余篇)。被评为首都名中医、卫生部有突出贡献中青年专家，享受国务院特殊津贴专家，中央保健先进个人；中医药科技推广工作先进个人。入选国家中医药管理局中医药传承与创新“百千万”人才工程岐黄学者；入选国家高层次人才特殊支持计划(万人计划)和百千万工程国家级人选

通讯作者: 唐旭东，E-mail：txdly@sina.com

中图分类号: R259

收稿日期: 2023-04-06

刊出日期: 2023-05-15

Diagnosis and treatment of atrophic gastritis and gastric precancerous lesions: key issues and countermeasures

- 1.
  Institute of Spleen-Stomach Disease, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, 100091, China
- 2.
  Graduate School of China Academy of Chinese Medical Sciences

More Information

Corresponding author: TANG Xudong, E-mail: txdly@sina.com

Received Date: 06 April 2023

Publish Date: 15 May 2023

摘要

摘要: 胃癌防治是我国恶性肿瘤防控面临的巨大挑战，探索出具有中国特色、流程合理、疗效明确的防治方案是解决问题的关键。萎缩性胃炎和癌前病变的存在为早诊、早治提供了可能，是胃癌二级预防工作体系的重心。40多年来，中医药在萎缩性胃炎和胃癌前病变的临床诊疗、基础研究、风险监测等方面取得了不少成绩，但也存在一定不足。本文对萎缩性胃炎及胃癌前病变的中医药研究历程进行回顾，对在的问题提出应对策略及对未来的发展进行展望，以期为建设有中国特色的胃癌二级防治体系提供参考。
- 萎缩性胃炎 /
- 胃癌前病变 /
- 中医药 /
- 研究策略
Abstract: Gastric cancer is a major challenge when it comes to preventing and controlling malignant tumors in China. The existence of atrophic gastritis and precancerous lesions provides the possibility for early diagnosis and treatment, and is the focus of secondary prevention of gastric cancer. During the past 40 years, Chinese Medicine research has made some significant achievements regarding the diagnosis, treatment, and prevention of atrophic gastritis and gastric precancerous lesions; however, deficiencies still exsit. This article reviews the history of Traditional Chinese Medicine research on atrophic gastritis and precancerous lesions, puts forward the strategies to deal with the existent problems and points out the future development, in order to provide reference for the construction of the secondary prevention and treatment system of gastric cancer with Chinese characteristics.
- atrophic gastritis /
- gastric precancerous lesions /
- Traditional Chinese Medicine /
- research strategy

HTML全文

参考文献(51)

[1]	Nagayo T. Histological diagnosis of biopsied gastric mucosae with special reference to that of borderline lesions[J]. Gann Monogr, 1971, 11: 245-256.
[2]	沈汉澄. 胃癌前病变: WHO新标准与综合干预[J]. 浙江临床医学, 2007, 9(11): 1441-1442. doi: 10.3969/j.issn.1008-7664.2007.11.001
[3]	国家消化系疾病临床医学研究中心(上海), 国家消化道早癌防治中心联盟, 中华医学会消化病学分会幽门螺杆菌学组, 等. 中国胃黏膜癌前状态和癌前病变的处理策略专家共识(2020年)[J]. 中华消化杂志, 2020, 40(11): 731-741. doi: 10.3760/cma.j.cn311367-20200915-00554
[4]	Sugano K, Tack J, Kuipers EJ, et al. Kyoto global consensus report on Helicobacter pylori gastritis[J]. Gut, 2015, 64(9): 1353-1367. doi: 10.1136/gutjnl-2015-309252
[5]	Rugge M, Correa P, Dixon MF, et al. Gastric dysplasia: the Padova international classification[J]. Am J Surg Pathol, 2000, 24(2): 167-176. doi: 10.1097/00000478-200002000-00001
[6]	Schlemper RJ, Riddell RH, Kato Y, et al. The Vienna classification of gastrointestinal epithelial neoplasia[J]. Gut, 2000, 47(2): 251-255. doi: 10.1136/gut.47.2.251
[7]	Dixon MF. Gastrointestinal epithelial neoplasia: Vienna revisited[J]. Gut, 2002, 51(1): 130-131. doi: 10.1136/gut.51.1.130
[8]	Hamilton SD, Vogelstein B, Kudo S, et al. World Health Organization classification of tumours: Pathology and genetics of tumours of the digestive system[M]//Hamilton SR, Aaltonen LA, eds. Tumours of the colon and rectum: Carcinoma of the colon and rectum. Lyon: IARC Press, 2000: 105-119.
[9]	Bosman FT, Carneiro F, Hruban RH, et al. World Health Organization classification of tumours of the digestive system[M]. 4th ed. Lyon: IARC Press, 2010: 195-334.
[10]	Fletcher C, Bridge J, Antonescu C. WHO classification of tumours editorial board. WHO Classification of Tumors Soft Tissue and Bone Tumours[M]. 5th ed. Lyon: IARC Press, 2020: 403-409.
[11]	中华医学会病理分会消化病理学组筹备组. 慢性胃炎及上皮性肿瘤胃黏膜活检病理诊断共识[J]. 中华病理学杂志, 2017, 46(5): 289-293. doi: 10.3760/cma.j.issn.0529-5807.2017.05.001
[12]	曹希和. 萎缩性胃炎的辨证与治疗[J]. 上海中医药杂志, 1983, 17(4): 17-18. doi: 10.16305/j.1007-1334.1983.04.011
[13]	张继泽, 单兆伟, 江杨清. 张泽生治疗萎缩性胃炎的经验[J]. 中医杂志, 1982, 27(8): 13-15, 19. doi: 10.13288/j.11-2166/r.1982.08.006
[14]	董建华, 田德录, 麻仲学, 等. 虚痞(慢性萎缩性胃炎癌前病变)中药治疗观察[J]. 中国医药学报, 1989, 4(6): 12-15, 78.
[15]	刘静, 孙国华. 抗肿瘤中药制剂的研制与开发[J]. 中国中医药信息杂志, 1994, 1(3): 22-25. https://www.cnki.com.cn/Article/CJFDTOTAL-XXYY199403010.htm
[16]	吴连恩, 徐景藩, 单兆伟. 益气活血方治疗慢性胃炎的临床研究[J]. 江苏中医, 1992, 27(1): 35-37.
[17]	田德录, 李军祥, 张林国, 等. 消痞灵冲剂治疗胃癌前期病变的临床观察[J]. 中国医药学报, 1998, 13(3): 32-35. doi: 10.3321/j.issn:1673-1727.1998.03.007
[18]	劳绍贤, 许鑫梅, 周福生, 等. 胃炎消治疗胃癌癌前期病变疗效分析[J]. 中药新药与临床药理, 1997, 8(2): 9-12, 63.
[19]	王垂杰, 张贵元, 周学文, 等. 阻癌胃泰冲剂治疗胃癌癌前病变的胃黏膜形态学及幽门螺杆菌变化[J]. 中国中西医结合脾胃杂志, 1998, 6(2): 79-81.
[20]	房静远, 杜奕奇, 刘文忠, 等. 中国慢性胃炎共识意见(2017年, 上海)[J]. 胃肠病学, 2017, 22(11): 670-687. doi: 10.3969/j.issn.1008-7125.2017.11.007
[21]	Pimentel-Nunes P, Libanio D, Marcos-Pinto R, et al. Management of epithelial precancerous conditions and lesions in the stomach(MAPS Ⅱ): European Society of Gastrointestinal Endoscopy(ESGE), European Helicobacter and Microbiota Study Group(EHMSG), European Society of Pathology(ESP), and Sociedade Portuguesa de Endoscopia Digestiva(SPED)guideline update 2019[J]. Endoscopy, 2019, 51(4): 365-388. doi: 10.1055/a-0859-1883
[22]	王萍, 李鹏, 陈萦晅, 等. 中国整合胃癌前病变临床管理指南[J]. 胃肠病学, 2021, 26(2): 91-111. doi: 10.3969/j.issn.1008-7125.2021.02.005
[23]	Rokkas T, Pistiolas D, Sechopoulos P, et al. The long-term impact of Helicobacter pylori eradication on gastric histology: a systematic review and meta-analysis[J]. Helicobacter, 2007, 12(Suppl 2): 32-38.
[24]	Kang JM, Kim N, Shin CM, et al. Predictive factors for improvement of atrophic gastritis and intestinal metaplasia after Helicobacter pylori eradication: a three-year follow-up study in Korea[J]. Helicobacter, 2012, 17(2): 86-95. doi: 10.1111/j.1523-5378.2011.00918.x
[25]	Shiotani A, Iishi H, Ishiguro S, et al. Epithelial cell turnover in relation to ongoing damage of the gastric mucosa in patients with early gastric cancer: increase of cell proliferation in paramalignant lesions[J]. J Gastroenterol, 2005, 40(4): 337-344. doi: 10.1007/s00535-004-1549-9
[26]	Schmidt PH, Lee JR, Joshi V, et al. Identification of a metaplastic cell lineage associated with human gastric adenocarcinoma[J]. Lab Invest, 1999, 79(6): 639-646.
[27]	Goldenring JR, Mills JC. Cellular Plasticity, Reprogramming, and Regeneration: Metaplasia in the Stomach and Beyond[J]. Gastroenterology, 2022, 162(2): 415-430. doi: 10.1053/j.gastro.2021.10.036
[28]	Halldorsdottir AM, Sigurdardottrir M, Jonasson JG, et al. Spasmolytic polypeptide-expressing metaplasia(SPEM)associated with gastric cancer in Iceland[J]. Dig Dis Sci, 2003, 48(3): 431-441. doi: 10.1023/A:1022564027468
[29]	Nomura S, Baxter T, Yamaguchi H, et al. Spasmolytic polypeptide expressing metaplasia to preneoplasia in H. felis-infected mice[J]. Gastroenterology, 2004, 127(2): 582-594. doi: 10.1053/j.gastro.2004.05.029
[30]	Weis VG, Sousa JF, LaFleur BJ, et al. Heterogeneity in mouse spasmolytic polypeptide-expressing metaplasia lineages identifies markers of metaplastic progression[J]. Gut, 2013, 62(9): 1270-1279. doi: 10.1136/gutjnl-2012-302401
[31]	Lennerz JK, Kim SH, Oates EL, et al. The transcription factor MIST1 is a novel human gastric chief cell marker whose expression is lost in metaplasia, dysplasia, and carcinoma[J]. Am J Pathol, 2010, 177(3): 1514-1533. doi: 10.2353/ajpath.2010.100328
[32]	Adkins-Threats M, Mills JC. Cell plasticity in regeneration in the stomach and beyond[J]. Curr Opin Genet Dev, 2022, 75: 101948. doi: 10.1016/j.gde.2022.101948
[33]	Toh JWT, Wilson RB. Pathways of Gastric Carcinogenesis, Helicobacter pylori Virulence and Interactions with Antioxidant Systems, Vitamin C and Phytochemicals[J]. Int J Mol Sci, 2020, 21(17): 6451. doi: 10.3390/ijms21176451
[34]	Businello G, Angerilli V, Parente P, et al. Molecular Landscapes of Gastric Pre-Neoplastic and Pre-Invasive Lesions[J]. Int J Mol Sci, 2021, 22(18): 9950. doi: 10.3390/ijms22189950
[35]	Xu W, Li B, Xu M, et al. Traditional Chinese medicine for precancerous lesions of gastric cancer: A review[J]. Biomed Pharmacother, 2022, 146: 112542. doi: 10.1016/j.biopha.2021.112542
[36]	Miki K. Gastric cancer screening by combined assay for serum anti-Helicobacter pylori IgG antibody and serum pepsinogen levels-"ABC method"[J]. Proc Jpn Acad Ser B Phys Biol Sci, 2011, 87(7): 405-414. doi: 10.2183/pjab.87.405
[37]	Tu H, Sun L, Dong X, et al. A Serological Biopsy Using Five Stomach-Specific Circulating Biomarkers for Gastric Cancer Risk Assessment: A Multi-Phase Study[J]. Am J Gastroenterol, 2017, 112(5): 704-715. doi: 10.1038/ajg.2017.55
[38]	Cai Q, Zhu C, Yuan Y, et al. Gastrointestinal Early Cancer Prevention & Treatment Alliance of China(GECA). Development and validation of a prediction rule for estimating gastric cancer risk in the Chinese high-risk population: a nationwide multicentre study[J]. Gut, 2019, 68(9): 1576-1587. doi: 10.1136/gutjnl-2018-317556
[39]	Kaji K, Hashiba A, Uotani C, et al. Grading of Atrophic Gastritis is Useful for Risk Stratification in Endoscopic Screening for Gastric Cancer[J]. Am J Gastroenterol, 2019, 114(1): 71-79. doi: 10.1038/s41395-018-0259-5
[40]	Rugge M, Meggio A, Pennelli G, et al. Gastritis staging in clinical practice: the OLGA staging system[J]. Gut, 200, 56(5): 631-636.
[41]	Capelle LG, de Vries AC, Haringsma J, et al. The staging of gastritis with the OLGA system by using intestinal metaplasia as an accurate alternative for atrophic gastritis[J]. Gastrointest Endosc, 2010, 71(7): 1150-1158. doi: 10.1016/j.gie.2009.12.029
[42]	Lee JWJ, Zhu F, Srivastava S, et al. Severity of gastric intestinal metaplasia predicts the risk of gastric cancer: a prospective multicentre cohort study(GCEP)[J]. Gut, 2022, 71(5): 854-863. doi: 10.1136/gutjnl-2021-324057
[43]	王萍, 史彬, 温艳东, 等. 胃癌前病变病证结合风险预测模型的构建研究[J]. 中国中西医结合杂志, 2018, 38(7): 773-778. https://www.cnki.com.cn/Article/CJFDTOTAL-ZZXJ201807001.htm
[44]	独思静, 国嵩, 方霜霜, 等. 慢性萎缩性胃炎中医药相关临床试验注册现状分析[J]. 中国中医药信息杂志, 2021, 28(7): 43-46. https://www.cnki.com.cn/Article/CJFDTOTAL-XXYY202107008.htm
[45]	Zhang M, Hu S, Min M, et al. Dissecting transcriptional heterogeneity in primary gastric adenocarcinoma by single cell RNA sequencing[J]. Gut, 2021, 70(3): 464-475. doi: 10.1136/gutjnl-2019-320368
[46]	Zhang P, Yang M, Zhang Y, et al. Dissecting the Single-Cell Transcriptome Network Underlying Gastric Premalignant Lesions and Early Gastric Cancer[J]. Cell Rep, 2019, 27(6): 1934-1947. doi: 10.1016/j.celrep.2019.04.052
[47]	Bockerstett KA, Lewis SA, Noto CN, et al. Single-Cell Transcriptional Analyses Identify Lineage-Specific Epithelial Responses to Inflammation and Metaplastic Development in the Gastric Corpus[J]. Gastroenterology, 2020, 159(6): 2116-2129. doi: 10.1053/j.gastro.2020.08.027
[48]	Hayakawa Y, Fox JG, Wang TC. Isthmus Stem Cells Are the Origins of Metaplasia in the Gastric Corpus[J]. Cell Mol Gastroenterol Hepatol, 2017, 4(1): 89-94. doi: 10.1016/j.jcmgh.2017.02.009
[49]	Li QY, Yang PH, Huang X, et al. Gastric Mucosa Pathology in Rats with Precancerous Lesions of Gastric Cancer with Spleen Deficiency and Blood Stasis[J]. Evid Based Complement Alternat Med, 2022, 2022: 1366597.
[50]	Dilaghi E, Lahner E, Annibale B, et al. Systematic review and meta-analysis: Artificial intelligence for the diagnosis of gastric precancerous lesions and Helicobacter pylori infection[J]. Dig Liver Dis, 2022, 54(12): 1630-1638. doi: 10.1016/j.dld.2022.03.007
[51]	Shi Z, Zhu C, Zhang Y, et al. Deep learning for automatic diagnosis of gastric dysplasia using whole-slide histopathology images in endoscopic specimens[J]. Gastric Cancer, 2022, 25(4): 751-760. doi: 10.1007/s10120-022-01294-w